Key result
Bioactive stent coatings reduce vascular immune responses, lowering inflammatory cytokines up to ~60%.
Why the study?
Do bioactive coatings for cardiovascular stents reduce immune responses and promote vascular healing in in vitro and in vivo models?
Do bioactive coatings for cardiovascular stents reduce immune responses and promote vascular healing in in vitro and in vivo models?
Answers are grounded in this paper and cite their sources.
Bioactive coatings for cardiovascular stents show promise in preclinical models for mitigating inflammation and promoting endothelial healing.
Cardiovascular disorders remain a leading cause of death worldwide, and the use of contemporary stents is paving the way for a profound shift in the field of cardiology. In the surgical process postimplantation, the graft or stent and host-immune interaction play a significant role in the healing process, thus it is a major challenge in healthcare. To address these challenges, recent advancements have introduced bioactive coatings with specialized modifications in stents to enhance their interaction with surrounding environment. These next-generation coatings are emphasizing strategies that reduce immune responses, that achieve up to ∼45% decrease in TNF-α expression and ∼60% reduction in IL-1β release in vitro, as well as ∼2.5-fold increase in M2/M1 macrophage ratio in animal models and promote vascular healing. In this review, we explore a range of coating materials, such as bioactive peptides, polymers, and composite systems, that have demonstrated the ability to elicit favorable biological responses while mitigating complications like inflammation, thrombosis, and restenosis. We explored the recent in vitro and in vivo research that shows the clinical potential of these coatings over times. Emerging innovations in this field highlight promising strategies for reducing inflammation and promoting endothelial healing in future cardiovascular stent designs.
No takes yet. Share an insight, caveat, or question.
Preetam et al. (2025) conducted a review in Cardiovascular disorders. Bioactive coatings for cardiovascular stents was evaluated. Bioactive coatings for cardiovascular stents reduce immune responses, achieving up to a 45% decrease in TNF-α and a 60% reduction in IL-1β in vitro, and a 2.5-fold increase in M2/M1 ratio in vivo.
Synapse has enriched 10 related papers. Consider them for comparative context: